SOPHARMA AD: Publication of a document prepared in accordance with Article 1(5)(ba) of Regulation (EU) 2017/1129

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No

/

2025

Date of issue:

2025-11-07

Short name of the issuer

SOPHARMA AD

Subject

Publication of a document prepared in accordance with Article 1(5)(ba) of Regulation (EU) 2017/1129

Official market - legal basis

Art. 56. 1. 2 of Act on Public Offering

Unofficial market - legal basis

Contents of the report:

Sofia, Bulgaria, 7 November 2025 – In accordance with the requirements of Article 21(3) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (“Regulation (EU) 2017/1129”), “Sopharma” AD (SFA: Bulgarian Stock Exchange AD, SPH: Warsaw Stock Exchange) has published a document prepared in accordance with Article 1(5)(ba) of Regulation (EU) 2017/1129. The document has been prepared for the purpose of seeking the admission and introduction of 404,359,704 shares in Sopharma AD to trading on the regulated (main) market operated by the Warsaw Stock Exchange. The document is available on the website (https://www.sopharmagroup.com/en/home/investors/prospectuses) of “Sopharma” AD.

Annexes

File

Description

Exemption document 07112025.rar

Publication of a document prepared in accordance with Article 1(5)(ba) of Regulation (EU) 2017/1129

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD

Farmaceutyczny (far)

(short name of the issuer)

(sector according to clasification

of the WSE in Warsow)

1220

Sofia

(post code)

(city)

IlienskoShosse

(street)

(number)

+359 2 813 42 00

+359 2 936 02 86

(phone number)

(fax)

(e-mail)

(web site)

nd

(NIP)

(REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

2025-11-07

Ognian Ivanov Donev

Executive Director